$EVMN
Evommune, Inc.
NYSE · Healthcare · Pharmaceutical Preparations · Palo Alto, CA
EVMN chart
What traders are saying about $EVMN
Latest postsEvommune, Inc. news
- RA Capital reported no trades in 60 days, yet its stake in Evommune (EVMN) was diluted.
Stock Titan ·
- Evommune to Present at Upcoming Investor Conferences - November 9, 2026
BioSpace ·
- Evommune to Present at Upcoming Investor Conferences
Yahoo Finance ·
- Investor talks for Evommune are scheduled in New York, London and Coral Gables
Stock Titan ·
- Evommune licenses oral VAV1 degrader EVO570 from Hinova in deal worth up to $1.1B
Dealroom ·
- Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development
marketbeat.com ·
- Hinova’s VAV1 MGD attracts $1B+ Evommune deal targeting JAK market
BioWorld News ·
- Evommune in-licenses EVO570 from Hinova Pharma for $1.1B
The Pharma Letter ·
- Fierce Pharma Asia—Boehringer’s $7.4B SBP deal; Fresenius’ sweeping biosim pact; A $1B molecular glue bet
Fierce Pharma ·
- Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap
BioSpace ·
- Evommune signs $1.1bn licence deal with Hinova for EVO570
pharmaceutical-technology.com ·
- Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
Yahoo Finance ·
Evommune, Inc. key financials
| USD | 2025 | 2024 |
|---|---|---|
| Revenue | $13.0M | $7.0M |
| Net income | -$68.9M | -$66.8M |
| Diluted EPS | $-11.22 | $-45.29 |
| Total assets (year end) | $224.9M | $76.1M |
| Cash and equivalents (year end) | $44.1M | $16.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Evommune, Inc.
- Ticker
- EVMN (NYSE)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Palo Alto, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 2044725
Frequently asked questions
What exchange is Evommune, Inc. listed on?
Evommune, Inc. trades on the NYSE under the ticker symbol EVMN.
What industry is Evommune, Inc. in?
Evommune, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Evommune, Inc. headquartered?
Evommune, Inc.'s business address on file with the SEC is in Palo Alto, CA.
When does Evommune, Inc.'s fiscal year end?
Evommune, Inc.'s fiscal year ends on December 31.
How much revenue did Evommune, Inc. report?
Evommune, Inc. reported $13.0M in revenue for calendar year 2025, according to its SEC filings.